A chimeric IL-10 Immunoglubulin fusion protein to treat Adenocarcinomas

The Portal is a joint project of MATTO and the MTTC. The development and implementation of the portal has been paid for by the MTTC, Beth Israel Deaconess Medical Center, Boston Biomedical Research Institute, Boston University, Brandeis University, Caritas St. Elizabeth's Medical Center, Boston Children's Hospital, Dana Farber Cancer Institute, Harvard University, Joslin Diabetes Center, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, McLean Hospital, Northeastern University, The Schepens Eye Research Institute, and Tufts University.

Intellectual Property

ID:		11179
IP Type:		Licensable Technology
Title:		A chimeric IL-10 Immunoglubulin fusion protein to treat Adenocarcinomas
Inventor:		Fox, James G; Davidson, Anne; Horwitz, Bruce ; Erdman, Susan
Summary:		The Technology: The inventors believe that a chimeric IL-10 molecule with an extended serum half-life may be effective in treating adenocarcinomas where tumors are characterized by the over-expression of a particular oncogene, Pim 1. The method is expected to be effective against such adenocarcinomas regardless of their tissue of origin and regardless of whether there has been a prior inflammatory condition. Research results suggest that IL-10 is probably exerting its therapeutic effects by suppressing IL-6. This suggests that other inhibitors of IL-6 should also be effective against adenocarcinomas over-expressing Pim-1, especially in cases where IL6 is also over-expressed. In vitro data generated by the inventors suggests that a chimeric protein in which IL-10 was fused to the constant region of murine IgG2a has the biological properties of IL-10 but has an extended serum half-life (10 days). In an immunodeficient mouse model infected with H. hepaticus, a lower bowel pathogen that induces inflammation and cancer, 92% of mice dosed with control Ig for 1 week were found to have cancer, while none of the mice treated with IL-10-Ig over the course of one week were found to have cancer. In another mouse model of GI cancer not associated with inflammation, preliminary data showed that untreated mice had an average of 63 tumors while treated mice had an average of 18 tumors. Based on these findings, the inventors believe that IL-10-Ig or a similar reagent could prove useful in the treatment of GI cancer regardless of its association with inflammation. Furthermore, they also believe that IL-10-Ig or a similar reagent could prove useful in treatment of breast and prostate cancer. Application: Use of IL-10-Ig or a similar reagent for the treatment of adenocarcinomas. Advantages: An alternative treatment option for adenocarcinomas.
Tech Type:		Therapeutic
URL:		http://www.partners.org/techtransfer/availabletechnologies/default.asp
Contact:		Amita Joshi, aajoshi@partners.org, 617-954-9526
Organization:		Brigham and Women's Hospital

Display all intellectual properties for Fox, James G; Davidson, Anne; Horwitz, Bruce ; Erdman, Susan
Display all intellectual properties for Brigham and Women's Hospital